Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Harmaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 6/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.97 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.97 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.97 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.61 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.61 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.61 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.53 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.53 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.97 |
| ▸ | MEN1 | O00255 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harmaline SCHEMBL177545 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL30055802 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL29626541 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL199260 | 0.99 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL31500129 | 0.90 | KDM4E (0.83) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL9481244 | 0.88 | KDM4E (0.80) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| SCHEMBL3877767 | 0.88 | KDM4E (1.00) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| Harmaline SCHEMBL28061967 | 0.87 | KDM4E (0.78) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| SCHEMBL1520427 | 0.84 | KDM4E (0.74) | KDM4EMEN1KMT2ACASP1CYP1A2 | |
| SCHEMBL28871756 | 0.82 | KDM4E (0.70) | KDM4EMEN1KMT2ACASP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-12592370-B2 | Screening with mass spectrometry for mycobacteria prior to cardiothoracic surgery | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-12545944-B2 | Method of detection | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-02-10 | — | — | US | disclosed |
| WO-2024254645-A1 | COMPOSITION AND METHOD TO TREAT, AMELIORATE OR PREVENT A PSYCHOLOGICAL, NEUROLOGICAL OR INFLAMMATORY DISORDER, AND METHOD FOR PREPARING COMPOSITION | Psychae Therapeutics Pty Ltd (AU) | 2024-12-19 | — | — | WO | disclosed |
| US-20230135821-A1 | SCREENING WITH MASS SPECTROMETRY FOR MYCOBACTERIA PRIOR TO CARDIOTHORACIC SURGERY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-05-04 | — | — | US | disclosed |
| EP-4038392-A1 | SCREENING WITH MASS SPECTROMETRY FOR MYCOBACTERIA PRIOR TO CARDIOTHORACIC SURGERY | Imperial College Innovations Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| EP-3589742-B1 | METHOD OF DETECTION | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021064426-A1 | SCREENING WITH MASS SPECTROMETRY FOR MYCOBACTERIA PRIOR TO CARDIOTHORACIC SURGERY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-04-08 | — | — | WO | disclosed |
| US-10188633-B2 | Identification of small molecules that facilitate therapeutic exon skipping | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-29 | — | — | US | disclosed |
| EP-2750715-B1 | IDENTIFICATION OF SMALL MOLECULES THAT ENHANCE THERAPEUTIC EXON SKIPPING | UNIV CALIFORNIA (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20050288234-A1 | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | SCHWARZ PHARMA AG (DE) | 2005-12-29 | — | — | US | disclosed |
| US-6601010-B1 | Force plate actometer | THE UNIVERSITY OF KANSAS | 2003-07-29 | — | — | US | disclosed |
| US-20030124320-A1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION | 2003-07-03 | — | — | US | disclosed |
| EP-0859610-A4 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 2002-05-15 | — | — | EP | disclosed |
| CN-1063966-C | Harmel preparation and preparing method thereof | WANG SHIYU (CN) | 2001-04-04 | — | — | CN | disclosed |
| US-6211360-B1 | DRUG ABRUSE THERAPY; PLANT EXTRACTS | ALBANY MEDICAL COLLEGE | 2001-04-03 | — | — | US | disclosed |
| EP-0859610-A1 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997005869-A1 | IBOGAMINE CONGENERS | ALBANY MEDICAL COLLEGE (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5591738-A | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | NDA INTERNATIONAL, INC. (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288234-A1 | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | VIP, PRSS12, GAP43 | GLA 3867/4885HTR7 1764/4885HTR2C 2017/4885 |
| US-10188633-B2 | Identification of small molecules that facilitate therapeutic exon skipping | RBM17, SMN1; SMN2, SNRPA1 | GLA 2490/4885HTR7 3984/4885HTR2C 4601/4885 |
| US-12592370-B2 | Screening with mass spectrometry for mycobacteria prior to cardiothoracic surgery | FABP3, ACADM, TST | GLA 1871/4885HTR7 3620/4885HTR2C 3434/4885 |
| US-12545944-B2 | Method of detection | PHOSPHO1, NAAA, LIPA | GLA 1012/4885HTR7 2096/4885HTR2C 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.